ArticleViruses2021
Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection.
Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Longitudinal SARS-CoV-2 seroprevalence among learners, parents, and teachers in a South African school community.Frontiers in public health · 2026Article
- Decoding the cross-immune pressure: Dengue's role in SARS-CoV-2 evolution.Computational and structural biotechnology journal · 2025Article
- Prevalence of SARS-CoV-2-specific antibodies in a sample of the Lithuanian population-based study in Spring 2023.Heliyon · 2024Article
- The presumed protective effect of IVIG against SARS-CoV-2 in inflammatory myopathy patients remains questionable.Rheumatology international · 2024Article
- Seroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave.International journal of environmental research and public health · 2023Article
- SARS-CoV-2 antibodies persist up to 12 months after natural infection in healthy employees working in non-medical contact-intensive professions.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Article
- Major Update 2: Antibody Response and Risk for Reinfection After SARS-CoV-2 Infection-Final Update of a Living, Rapid Review.Annals of internal medicine · 2023Review
- Durability and extent of protection of SARS-CoV-2 antibodies among patients with COVID-19 in Metro Manila, Philippines.Frontiers in immunology · 2023Article
- How immune breakthroughs could slow disease progression and improve prognosis in COVID-19 patients: a retrospective study.Frontiers in immunology · 2023Article
- Article
- Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021.Scientific reports · 2022Article
- Article
- High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020-2021.Frontiers in medicine · 2022Article
- Characteristics and Prognosis of Antibody Non-responders With Coronavirus Disease 2019.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDynamics of antibody responses were investigated after a SARS-CoV-2 outbreak in a private company during the first wave of the pandemic.
methodsWorkers of a sewing company (Lithuania) with known SARS-CoV-2 RT-PCR result during the outbreak (April 2020) were invited to participate in the study. Virus-specific IgG and IgM were monitored 2, 6 and 13 months after the outbreak via rapid IgG/IgM serological test and SARS-CoV-2 S protein-specific IgG ELISA.
resultsSix months after the outbreak, 95% (CI 86-99%) of 59 previously infected individuals had virus-specific antibodies irrespective of the severity of infection. One-third of seropositive individuals had virus-specific IgM along with IgG indicating that IgM may persist for 6 months. Serological testing 13 months after the outbreak included 47 recovered individuals that remained non-vaccinated despite a wide accessibility of COVID-19 vaccines. The seropositivity rate was 83% (CI 69-91%) excluding one case of confirmed asymptomatic reinfection in this group. Between months 6 and 13, IgG levels either declined or remained stable in 31 individual and increased in 7 individuals possibly indicating an exposure to SARS-CoV-2 during the second wave of the pandemic.
conclusionsDetectable levels of SARS-CoV-2-specific antibodies persist up to 13 months after infection for the majority of the cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.